Psilocybin
Jennifer Chesak Writes About Psilocybin and Women – Podcast Episode #36
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Jennifer Chesak, the author of The Psilocybin Handbook for Women. Jennifer…
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Jennifer Chesak, the author of The Psilocybin Handbook for Women.
Jennifer is the author of the forthcoming book “Psilocybin for Women,” to be published by Ulysses Press and distributed by Simon & Schuster in 2023.
She is a Nashville-based freelance journalist, editor, fact-checker, and adjunct professor with more than two decades of experience. She earned her Master of Science in Journalism from Northwestern University’s Medill. Her writing has appeared in Washington Post, The Daily Beast, Healthline, Verywell, Greatist, Prevention, Runner’s World, Trail Runner, Women’s Running, Health, Better Homes and Gardens, Real Simple, and more. She also serves on Healthline’s Medical Integrity Team. In addition to editorial work, her cornucopia of clips showcases a robust lineup of content marketing for several global and national brands.
Teaching is also a passion for Jennifer. She is as an adjunct professor at Belmont University, where she teaches copyediting, nonfiction and technical editing, and media studies. In addition to mentoring students in Middle Tennessee State University’s certificate in writing program (MTSU Write), Jennifer is also the managing editor of the university’s literary magazine SHIFT. And she enjoys teaching evening and weekend workshops through Nashville’s literary nonprofit The Porch.
Stay tuned for more great Psychedelic Invest Podcast episodes… happening weekly.
If you just found out about the podcast, we encourage you to check out the Psychedelic Invest Podcast page or subscribe to the show on your favorite audio platform to binge and catch up.
The Transcription is Coming Soon
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics5 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001